Skip to main navigation menu Skip to main content Skip to site footer

No. 4 (2024)

ORIRGINAL RESEARCH

An Observational Study of Psychopharmacotherapy for Extremely Underweight Inpatients with Anorexia Nervosa

https://doi.org/10.21265/PSYPH.2024.29.70.001

Published 2024-12-30

  • O.A. Karpenko
    • ,
  • T.S. Syunyakov
    • ,
  • A.K. Aleksanian
    • ,
  • E.V. Mazurova
    • ,
  • Yu.A. Nikolkina
    • ,
  • O.V. Andrianova
    • ,
  • L.E. Gilmutdinova
    • ,
  • E.V. Shakhova
    • ,
  • A.A. Shafarenko
    • ,
  • L.S. Satyanova
    • ,
  • G.P. Kostyuk

O.A. Karpenko
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

T.S. Syunyakov
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

A.K. Aleksanian
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

E.V. Mazurova
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

Yu.A. Nikolkina
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

O.V. Andrianova
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

L.E. Gilmutdinova
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

E.V. Shakhova
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

A.A. Shafarenko
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

L.S. Satyanova
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

G.P. Kostyuk
Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department

Abstract

Background. There is a lack of evidence on psychopharmacological treatment for patients with extreme anorexia nervosa (AN); however, these patients seek medical help in mental health settings. There is a need for information on treatment approaches for this group of patients.

Objective — to analyze psychopharmacological treatment patterns of inpatients with AN with extremely low body mass index (BMI) < 13 kg/m2 during hospital treatment and to assess treatment outcomes in 1–2 years after hospital discharge.

Methods. Retrospective medical chart review (n = 47) with patient follow-up assessment at 1–2 years after discharge. Treatment outcomes were assessed using: body mass index (BMI) at discharge and follow-up, occupation, quality of life (QoL), satisfaction with treatment, mortality. Quality of life was assessed using World Health Organization Quality of Life Questionnaire (brief version). Treatment satisfaction was assessed using Satisfaction with Hospital Treatment Questionnaire.

Results. All patients received complex therapy; olanzapine was the most frequently prescribed antipsychotic (54.5 %), mirtazapine was the most frequently used antidepressant (57.1 %), and hydroxyzine was used in 55.3 % of patients. At the discharge 63,8% patients achieved BMI > 16 kg/m2 and 72.7 % had BMI > 16 kg/m2 at the follow-up. All patients were alive at the time of follow-up, 88.9 % were occupied. Age and illness duration negatively correlated with BMI at discharge (r = –0.29 and r = –0.31, respectively, p < 0.05), but not with BMI at follow-up. Quality of life exceeded the population norms. Patients were highly satisfied with the hospital treatment (satisfaction rates exceeded 70 %).

Conclusion. Olanzapine, mirtazapine and hydroxyzine are the most commonly prescribed drugs for the treatment of extremely underweight patients with AN. There is a need for randomized controlled trials of psychopharmacological treatment of AN.

Keywords

anorexia nervosa, severe anorexia nervosa, extremely low weight, psychopharmacology, olanzapine, mirtazapine

PDF (Русский)

References

  1. Wonderlich S.A., Bulik C.M., Schmidtet U. et al. Severe and enduring anorexia nervosa: Update and observations about the current clinical reality // International Journal of Eating Disorders. – 2020. – Vol. 53 (8). – Pp. 1303–1312. – https://doi.org/10.1002/eat.23283
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. – Washington, DC: American Psychiatric Association, 2013.
  3. World Health Organization. International classification of diseases, eleventh revision (ICD-11), 2019. – Available at: https://icd.who.int/browse11 (accessed September 12, 2024).
  4. Royal College of Psychiatrists, Royal College Physicians, Royal College of Pathologists. MARSIPAN: Management of really sick patients with anorexia nervosa // College Report CR189: Royal College of Psychiatrists. 2014.
  5. Marzola E., Martini M., Brustolin A. et al. Inpatients with severe-enduring anorexia nervosa: understanding the “enduringness” specifier // European Psychiatry. – 2021. – Vol. 64 (1). – Art. e44. – https://doi.org/10.1186/s40337-022-00648-0
  6. Hay P., Touyz S. Classification challenges in the field of eating disorders: can severe and enduring anorexia nervosa be better defined? // Journal of Eating Disorders. – 2018. – Vol. 6. – Pp. 1–3. – https://doi.org/10.1186/s40337-018-0229-8
  7. Rosling A.M., Sparén P., Norringet C. et al. Mortality of eating disorders: A follow‐up study of treatment in a specialist unit 1974–2000 // International Journal of Eating Disorders. – 2011. – Vol. 44 (4). – Pp. 304–310. – https://doi.org/10.1002/eat.20827
  8. Gibson D., Watters A., Cost J. et al. Extreme anorexia nervosa: medical findings, outcomes, and inferences from a retrospective cohort // Journal of Eating Disorders. – 2020. – Vol. 8. – Pp. 1–10. – https://doi.org/10.1186/s40337-020-00303-6
  9. Robinson P., Jones W.R. MARSIPAN: Management of really sick patients with anorexia nervosa // BJPsych Advances. – 2018. – Vol. 24 (1). – Pp. 20–32. – https://doi.org/10.1192/bja.2017.2
  10. Robinson P.H., Nicholls D. Critical care for anorexia nervosa. – Cham: Springer, 2015. – https://doi.org/10.1007/978-3-319-08174-8
  11. Proulx-Cabana S., Metras M., Taddeo D. et al. To improve the initial inpatient management of adolescents admitted with severe anorexia nervosa: A narrative review and a convenient protocol // Nutrients. – 2022. – Vol. 14 (1). – Art. 229. – https://doi.org/10.3390/nu14010229
  12. Touyz S., Le Grange D., Lacey Het al. Treating severe and enduring anorexia nervosa: A randomized controlled trial // Psychological Medicine. – 2013. – Vol. 43 (12). – Pp. 2501– 2511. – https://doi.org/10.1017/s0033291713000949
  13. Hay P.J., Touyz S., Sud R. Treatment for severe and enduring anorexia nervosa: a review // Australian & New Zealand Journal of Psychiatry. – 2012. – Vol. 46 (12). – Pp. 1136– 1144. – https://doi.org/10.1177/0004867412450469
  14. Himmerich H., Lewis Y.D., Conti C. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders // The World Journal of Biological Psychiatry. – 2023. – Vol. 24 (8). – Pp. 643– 706. – https://doi.org/10.1080/15622975.2023.2179663
  15. National Institute for Health and Care Excellence. NICE eating disorders guidelines: Eating disorders: Recognition and treatment. – London, England: NICE, 2017.
  16. Garner D.M., Anderson M.L., Keiper C.D. et al. Psychotropic medications in adult and adolescent eating disorders: clinical practice versus evidence-based recommendations // Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity. – 2016. – Vol. 1. – Pp. 395–402. – https://doi.org/10.1007/s40519-016-0253-0
  17. Gorrell S., Lebow J., Kinaszet K. et al. Psychotropic medication use in treatment‐seeking youth with eating disorders // European Eating Disorders Review. – 2020. – Vol. 28 (6). – Pp. 739–749. – https://doi.org/10.1002/erv.2788
  18. Frank G.K.W., Shott M.E. The role of psychotropic medications in the management of anorexia nervosa: Rationale, evidence and future prospects // CNS Drugs. – 2016. – Vol. 30 (5). – Pp. 419–442. – https://doi.org/10.1007/s40263-016-0335-6
  19. Popov M.Y., Lepik O.V., Kozlovskii V.L. et al. Pharmacological strategies for appetite modulation in eating disorders: A narrative review // Consortium Psychiatricum. – 2023. – Vol. 4 (2). – Art. 79. – https://doi.org/10.17816/CP6150
  20. Blanchet C., Guillaume S., Bat-Pitault F. et al. Medication in AN: a multidisciplinary overview of meta-analyses and systematic reviews // Journal of Clinical Medicine. – 2019. – Vol. 8 (2). – Art. 278. – https://doi.org/10.3390/jcm8020278
  21. McMahon J., Green I., Omitogunet T. et al. Psychoeducation on medication for people with anorexia nervosa: A quality improvement project. Weight Loss — A Multidisciplinary Perspective // IntechOpen. – 2024. – https://doi.org/10.5772/intechopen.1006307
  22. World Health Organization. International Statistical Classification of Diseases and related health problems: Alphabetical index. – 2004. – Vol. 3.
  23. World Health Organization. WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: Field trial version. – 1996.
  24. Лутова Н.Б., Борцов А.В., Вид В.Д. Метод оценки субъективной удовлетворенности психически больных лечением в психиатрическом стационаре: методические рекомендации. – М.: Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева, 2007. – 17 с.
  25. Breiner H., Stroud C., Bonnie R.J. Investing in the health and well-being of young adults. – Washington, DC: The National Academies Press, 2015. – https://doi.org/10.17226/18869
  26. Kaufmann L.K., Moergeli H., Milos G.F. Lifetime weight characteristics of adult inpatients with severe anorexia nervosa: maximal lifetime BMI predicts treatment outcome // Frontiers in Psychiatry. – 2021. – Vol. 12. – Art. 682952. – https://doi.org/10.3389/fpsyt.2021.682952
  27. Guinhut M., Melchior J.C., Godart N. et al. Extremely severe anorexia nervosa: Hospital course of 354 adult patients in a clinical nutrition-eating disorders-unit // Clinical Nutrition. – 2021. – Vol. 40 (4). – Pp. 1954–1965. – https://doi.org/10.1016/j.clnu.2020.09.011
  28. Mauri M., Miniati M., Mariani M.G., Ciberti A., Dell’Osso L. Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: A nine-case chart review // Eat Weight Disord. – 2013. – Vol. 3. – Pp. 329–332. – https://doi.org/10.1007/s40519-013-0052-9
  29. Frank B., Arnold S., Jaite C., Correll C.U. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: A retrospective chart review of hospitalized children and adolescents // J Eat Disord. – 2023. – Vol. 1. – Art. 151. – https://doi.org/10.1186/s40337-023-00862-4
  30. Kolar D.R., Meule A., Naab S. et al. Early within‐person weight gain and variability during inpatient treatment for anorexia nervosa: Age‐dependent effects on treatment outcome // European Eating Disorders Review. – 2022. – Vol. 30 (4). – Pp. 328–340. – https://doi.org/10.1002/erv.2893
  31. Meule A., Kolar D.R., Rauh E. et al. Comparing illness duration and age as predictors of treatment outcome in female inpatients with anorexia nervosa // Eating Disorders. – 2023. – Vol. 31 (3). – Pp. 274–284. – https://doi.org/10.1080/10640266.2022.2114586
  32. Glasofer D.R., Muratore A.F., Attia E. et al. Predictors of illness course and health maintenance following inpatient treatment among patients with anorexia nervosa // Journal of Eating Disorders. – 2020. – Vol. 8. – Pp. 1–10. – https://doi.org/10.1186/s40337-020-00348-7
  33. Bissada H., Tasca G. A., Barber A. M et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial // American Journal of Psychiatry. – 2008. – Vol. 165 (10). – Pp. 1281–1288. – https://doi.org/10.1176/appi.ajp.2008.07121900
  34. Attia E., Steinglass J.E., Walsh B.T. et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial // American Journal of Psychiatry. – 2019. – Vol. 176 (6). – Pp. 449–456. – https://doi.org/10.1176/appi.ajp.2019.1766correction1
  35. Мосолов С.Н., Калинин В.В. Применение атипичных нейролептиков в психоневрологической практике // Методические рекомендации Министерства здравоохран РФ. – М., 1998.
  36. Мосолов С.Н., Калинин В.В., Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении (мета-анализ оригинальных исследований оланзапина, рисперидона, кветиапи клозапина и галоперидола) // Новые достижения в терапии психических заболеваний. – М.: БИНОМ. Лаборатория знаний, 2002. – С. 82–94.
  37. Carrot B., Radon L., Hubert T. et al. Are lifetime affective disorders predictive of long-term outcome in severe adolescent anorexia nervosa? // European Child & Adolescent Psychiatry. – 2017. – Vol. 26. – Pp. 969–978. – https://doi.org/10.1007/s00787-017-0963-5
  38. Mattar L., Thiébaud M.R., Huas C. et al. Depression, anxiety and obsessive–compulsive symptoms in relation to nutritional status and outcome in severe anorexia nervosa // Psychiatry Research. – 2012. – Vol. 200 (2–3). – Pp. 513–517. – https://doi.org/10.1016/j.psychres.2012.04.032
  39. Stahl S.M. Stahl’s essential psychopharmacology: prescriber’s guide antidepressants. – Cambridge: Сambridge University Press, 2014. – 824 p. https://doi.org/10.1017/9781108921275.045
  40. Marvanova M., Gramith K. Role of antidepressants in the treatment of adults with anorexia nervosa // Mental Health Clinician. – 2018. – Vol. 8 (3). – Pp. 127–137. – https://doi.org/10.9740/mhc.2018.05.127
  41. Wang T.S., Chou Y.H., Shiah I.S. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression // Progress in Neuro-Psychopharmacology and Biological Psychiatry. – 2006. – Vol. 30 (2). – Pp. 306–309. – https://doi.org/10.1016/j.pnpbp.2005.10.004
  42. Stiles-Shields C., Touyz S., Hay P. et al. Therapeutic alliance in two treatments for adults with severe and enduring anorexia nervosa // International Journal of Eating Disorders. – 2013. – Vol. 46 (8). – Pp. 783–789. – https://doi.org/10.1002/eat.22187
  43. Fewell L.K., Levinson C.A., Stark L. Depression, worry, and psychosocial functioning predict eating disorder treatment outcomes in a residential and partial hospitalization setting // Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity. – 2017. – Vol. 22 (2). – Pp. 291–301. – https://doi.org/10.1007/s40519-016-0357-6
  44. Cowman M., Godfrey E., Walsh T. et al. Measures of social and occupational function in early psychosis: A systematic review and meta-analysis // Schizophrenia Bulletin. – 2024. – Vol. 50 (2). – Pp. 266–285. – https://doi.org/10.1093/schbul/sbad062
  45. Skevington S.M., Lotfy M., O›Connell K.A. The World Health Organization›s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group // Quality of life Research. – 2004. – Vol. 13. – Pp. 299–310. – https://doi.org/10.1023/B:QURE.0000018486.91360.00
  46. Springfield C.R., Bonfils K.A., Chernov N.V. et al. The paradoxical moderating effects of metacognition in the relationships between self-esteem, depressive symptoms, and quality of life in anorexia and bulimia // Consortium Psychiatricum. – 2023. – Vol. 4 (2). – Art. 6. – https://doi.org/10.17816/CP6139
  47. Ágh T., Kovács G., Supina D. et al. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder // Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity. – 2016. – Vol. 21. – Pp. 353–364. – https://doi.org/10.1007/s40519-016-0264-x
  48. Goddard E., Hibbs R., Raenker S., et al. A multi-centre cohort study of short term outcomes of hospital treatment for anorexia nervosa in the UK // BMC Psychiatry. – 2013. – Vol. 13. – Pp. 1–14. – https://doi.org/10.1186/1471-244X-13-287
  49. Mond J.M., Hay P.J., Rodgers B. et al. Assessing quality of life in eating disorder patients // Quality of Life Research. – 2005. – Vol. 14. – Pp. 171–178. – https://doi.org/10.1007/s11136-004-2657-y

Downloads

Download data is not yet available.